The effect of hormone therapy and rloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women

Menopause

Volumn 11, Issue 3, 2004, Pages 299-305

  Christodoulakos, George E ^a   Panoulis, Constantinos P C ^a   Lambrinoudaki, Irene V ^a,c   Botsis, Dimitrios S ^a   Dendrinos, Spyros G ^a   Economou, Emanuel ^b   Creatsas, George C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

Estrogen; Hormone therapy; Matrix metalloproteinase; Raloxifene

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; GELATINASE A; GELATINASE B; NORETHISTERONE ACETATE; PLACEBO; RALOXIFENE; DRUG DERIVATIVE; NORETHISTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; MULTICENTER STUDY; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; ARTERIOSCLEROSIS; BLOOD; GREECE; MIDDLE AGED;

ARTERIOSCLEROSIS; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; GREECE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 4043165746     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000097848.95550.07     Document Type: Article

References (46)

1. Lopes N, Vasudevans SS, Alvarez RJ, Binkley PF, Goldschmidt PJ. Pathophysiology of plaque instability: insights at the genomic level. Prog Cardiovasc Dis 2002;44:323-338.
2. Stevenson JC. Cardiovascular effects of estrogens. J Steroid Biochem Mol Biol 2000;74:387-393.
3. Epstein JA, Rader DJ, Parmacek MS. Perspective: cardiovascular disease in the postgenomic era - lessons learned and challenges ahead. Endocrinology 2002;143:2045-2050.
4. Robbie L, Libby P. Inflammation and atherothrombosis. Ann NY Acad Sci 2001;947:167-179.
5. Farzati A, Esposito K, Colacurci N, Fornato F, Chiantera V, Farzati B. Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women. Fertil Steril 2002;77:476-480.
6. Seljeflot I, Arnesen H, Hofsat AE, Os I. Reduced expression of endothelial cell markers after long term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 2000;83:944-948.
7. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am J Cardiol 2002;90:7F-10F.
8. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-1802.
9. The Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
10. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
11. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002;106:1771-1776.
12. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.
13. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2000;85:214-218.
14. Christodoulakos G, Lambrinoudaki I, Panoulis C, Rizos D, Coutoukos J, Creatsas G. Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women. Fertil Steril 2003;79:455-456.
15. Creatsas GC, Malamitsi-Puchner AB, Hassan EA, Economou EB, Aravantinos DI. Endothelin serum levels in primary amenorrheic adolescents before and after estrogen treatment. J Soc Gynecol Invest 1996;3:350-353.
16. Christodoulakos G, Panoulis C, Kouskouni E, Chondros C, Dendrinos S, Creatsas G. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis. Gynecol Endocrinol 2002;16:9-17.
17. Rahimian R, Laher I, Dube G, van Breeman C. Estrogen and selective estrogen receptor modulator LY 117018 enhance release of nitric oxide in ref aorta. J Pharmacol Exp Ther 1997;283:116-122.
18. Van Baal WM, Emeis JJ, Kenemans P, et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999;29:913-921.
19. Bui MN, Arai AE, Hathaway L, Waclawiw MA, Csako G, Cannon RO 3rd. Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women. Am J Cardiol 2002;90:82-85.
20. Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein 1996;49:7-19.
21. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001;38:581-587.
22. Sato H, Seiki M. Membrane-type matrix metalloproteinases (MTMMPs) in tumor metastasis. J Biochem 1996;119:209-215.
23. Shah PK. Pathophysioloogy of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis 2002;44:357-368.
24. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
25. Galis ZS, Khtzi JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res 2002;90:251-262.
26. Ardans JA, Blum A, Mangan PR, Wientroub S, Cannon RO 3rd, Wahl LM. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler Thromb Vasc Biol 2001;21:1265-1268.
27. Nickelsen T, Creatsas G, Rechberger T, et al. Differential effects of raloxifene and continuous-combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox I study. Climacteric 2001;4:320-331.
28. Guccione M, Silbiger S, Lei J, Neugarten J. Estradiol upregulates mesangial cell MMP-2 activity via the transcription factor AP-2. Am J Physiol Renal Physiol 2002;282:F164-169.
29. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17β-estradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998;1406:169-174.
30. Moalli PA, Klingensmith WL, Meyn LA, Zyczynski HM. Regulation of matrix metalloproteinase expression by estrogen in fibroblasts that are derived from the pelvic floor. Am J Obstet Gynecol 2002;187:72-79.
31. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEP1) Study. Circulation 1999;100:717-722.
32. Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003;17:119-124.
33. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 2000;36:312-318.
34. Rossouw JR. Hormones, genetic factors and gender differences in cardiovascular disease. Cardiovasc Res 2002;53:550-557.
35. Langer RD. Hormone replacement and the prevention of cardiovascular disease. Am J Cardiol 2002;89:36E-46E.
36. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001;39:380-384.
37. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential ef-fects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-4222.
38. Koh KK, Son JW, Ahn JY, et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002;22:e19-23.
39. Porter KE, Naik J, Turner NA, Dickinson T, Thompson MM, London NJ. Simvastatin inhibits human saphenus vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 2002;36:150-157.
40. Nagashima H, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002;36:158-163.
41. Son JW, Koh KK, Ahn JY, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82.
42. Rossouw JE. Early risk of cardiovascular events after commencing hormone replacement therapy. Curr Opin Lipidol 2001;12:371-375.
43. Kellen JA, Raloxifene. Curr Drug Targets 2001;2:423-425.
44. Simoncini T, DeCatarina R, Genazzani AR. Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Clin Endocrinol Metab 1999;84:815-18.
45. Wolczynski S, Surazynski A, Swiatecka J, Palka J. Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecol Endocrinol 2001;15:225-33.
46. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporptic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.